October 01, 2025

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001.
Scrip Code: 543434

National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051.
NSE Symbol: SUPRIYA

Dear Sir/Madam,

Sub: Completion of WHO GMP Audit at Ambernath facility of the Company.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 this is to inform you that the World Health Organisation (WHO) on September 2, 2025 had conducted WHO GMP for Inhalation Dosages

The Audit was conducted and upon completion WHO has issued WHO-GMP certificate for our Ambernath facility and declared that the Company is GMP complaint and can now carry out production and sale at our said facility and is eligible for further distribution of products in Rest of the World markets/ eligible markets.

The details are enclosed herewith as Annexure A to this disclosure.

Kindly take this information on records.

Thanking you,

For Supriya Lifescience Limited

Prachi Suhas Sathe

Digitally signed by Prachi Suhas Sathe
Date: 2025.10.01 12:32:06 +05'30'

Prachi Sathe
Company Secretary & Compliance Officer

Corporate office *:* 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: **supriya@supriyalifescience .com** Website: **www.supriyalifescience.com**

Factory *:* A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

Annexure A

Sr. No.	Particulars	Brief Details
1.	Name of the authority.	World Health Organisation
2.	Nature and details of the action(s) taken, initiated or order(s) passed.	The Audit was conducted and upon completion WHO has issued WHO-GMP certificate for our Ambernath facility and declared that the Company is GMP complaint and can now carry out production and sale at our said facility and is eligible for further distribution of products in Rest of the World markets/ eligible markets.
3.	Date of receipt of direction or order, including any adinterim or interim orders, or any other communication from the authority	September 30, 2025
4.	Details of the violation(s) /contravention(s) committed or alleged to be committed	Nil
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible.	We do not expect this development to have any material impact on the current business operations or existing supplies from this facility. 6